From: Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients
 | All patients | Patients with BP-ONJ | Patients without BP-ONJ | Difference |
---|---|---|---|---|
Number (percentage) | 78 (100%) | 16 (21%) | 62 (80%) | Â |
Age at examination (SD) | 63.5 (10.1) | 61.9 (21.0) | 64.1 (10.5) | p = 0.18 |
Age at MM diagnosis | 59.8 (11.1) | 54.1 (8.8) | 61.3 (11.2) | p = 0.02 |
Men | 47 | 9 | 38 | p = 0.78 |
Women | 31 | 7 | 24 | Â |
MM stage I | 17 (22%) | 3 (4%) | 14 (18%) | Â |
MM stage II | 13 (17%) | 2 (3%) | 11 (14%) | p = 0.79 |
MM stage III | 48 (62%) | 11 (14%) | 37 (47%) | Â |
Bisphosphonate infusions | 28.1 | 48.4 (range 9 - 111) | 23.3 (range 1 - 104) | p < 0.001 |
Zoledronate | Â | Â | Â | Â |
Patients | 49 (63%) | 4 (5%) | 45 (58%) | Â |
Infusions | 15 | 21 | 15 | Â |
Pamidronate + zoledronate | Â | Â | Â | Â |
Patients (percentage) | 20 (26%) | 9 (12%) | 11 (14%) | Â |
infusions | 33, 22 | 26, 30 | 39, 15 | Â |
Ibandronate + zoledronate | Â | Â | Â | p = 0.001 |
Patients (percentage) | 6 (8%) | 1 (1%) | 5 (6%) | Â |
infusions | 6, 15 | 4, 28 | 7, 12 | Â |
Pamidronate + zoledronate + ibandroante | Â | Â | Â | Â |
Patients (percentage) | 3 (4%) | 2 (3%) | 1 (%) | Â |
infusions | 38, 20, 5 | 27, 28, 3 | 59, 5, 10 | Â |
Corticosteroids | 59 (76%) | 13 (17%) | 46 (61%) | p = 0.75 |
Chemotherapy | 64 (82%) | 13 (17%) | 51 (67%) | p = 1.0 |
Diabetes mellitus | 6 (8%) | 2 (3%) | 4 (5%) | p = 0.6 |
Further malignant diseases | 3 (4%) | 0 | 3 (4%) | p = 1.0 |
Smoker | 8 (10%) | 1 (1%) | 7 (9%) | p = 1.0 |
Patients with all teeth in situ | 8 (10%) | 0 | 8 (10%) | p = 0.2 |
Caries | 16 (21%) | 2 (3%) | 14 (18%) | p = 0.50 |
Denture | 37 (47%) | 9 (12%) | 28 (36%) | p = 0.58 |